Recorded Presentation from the NCCN Pharmacy Updates: CAR-T Therapy in Multiple Myeloma

Recorded Presentation from the NCCN Pharmacy Updates: CAR-T Therapy in Multiple Myeloma is organized by National Comprehensive Cancer Network (NCCN) and will be held from May 24, 2022 - May 20, 2023.,,Description:,Several new options have recently been approved for the treatment of relapsed/refractory multiple myeloma, most notably, CAR T-cell therapy. Pharmacists should be aware of the new data and recommendations surrounding this novel agent and how they relate to improvements in patient survival and quality of life. It is also important to be aware of the potential for unique and potentially severe adverse events that can occur with these therapies. Therefore, patient education is especially important when discussing the possibility of adverse events and the need to report symptoms to health care teams to avoid severe complications.,,Learning Objectives:,Following this activity, participants should be able to:,• Summarize clinical evidence for the approval of chimeric antigen receptor T-cell (CAR-T) therapy, idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel), for the treatment of relapsed/refractory multiple myeloma (MM). ,• Identify key patient counseling and monitoring considerations for CAR-T therapy, idecabtagene vicleucel and ciltacabtagene autoleucel, for the treatment of relapsed/refractory MM. ,• Demonstrate ways to manage adverse events associated with CAR-T therapy, idecabtagene vicleucel and ciltacabtagene autoleucel, for the treatment of relapsed/refractory MM.,,Additional details will be posted as soon as information is available.